Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BGE-102

Small molecule · developed by BioAge Labs

Phase 2 Most advanced trial
BIOA Developer
1 Registered trials

What is BGE-102?

BGE-102 is a drug studied in obesity and cardiovascular risk.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Small molecule
Therapy area
Metabolic
Developer
BioAge Labs, Inc. (BIOA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07656727 Phase 2 Obesity and Cardiovascular Risk Active not recruiting BIOA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Obesity and Cardiovascular Risk

More from BioAge Labs

Follow BIOA, the company behind BGE-102

See BIOA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BIOA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.